Turning Science Into
SynDevRx, Inc. (“SDX”) Cambridge, Massachusetts, established in 2007, is
developing new and effective treatments for metabolic-related diseases
including pre-diabetes, diabetes, obesity, dyslipidemia and fatty liver
disease as well as treatments for cancer.
Our treatments are best-in-class MetAP2 inhibitors of the fumagillin
drug class. SynDevRx lead compound, SDX-7320*, is a polymer
conjugate of fumagillol which releases a pharmacologically active,
novel fumagillol derivative in vivo. In animal
models, SDX-7320 has shown improved activity relative to small molecule
compounds in the fumagillin class.
development approach improves both the efficacy and safety of low
molecular weight fumagillol-based drugs while reducing systemic drug
exposure compared to the small molecule drug. The expected
clinical consequence of lowering systemic exposure is an improved
SDX development program targets metabolic-related diseases as well as
cancer. Our compounds inhibit MetAP2 - an enzyme which
independent research has shown to be important in the regulation of a
number of cellular processes including protein turnover, protein
targeting and cell proliferation. The polymer conjugation
chemistry keeps the active drug inert in general circulation thereby
greatly reducing systemic toxicities. The conjugates also
exhibit longer half-lives than fumagillol small molecules, which allows
for less frequent dosing schedules than small molecules.
compound is currently in development and is not approved by the FDA (or
any other regulatory authority) for clinical use.
SynDevRx is a registered trademark of SynDevRx, Inc.